CD48 and neoplasm: When injected with SLAMF2+ and SLAMF2- metastatic B16 melanoma cells, wild-type mice poorly rejected the SLAMF2+ melanoma cells compared to SLAMF2- tumor cells, suggesting an inhibitory effect of SLAMF4-SLAMF2 interaction on melanoma cells [89].